Key points are not available for this paper at this time.
Background: The long-term cancer safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in real-world settings remains unclear, with limited long-term clinical and observational studies. We clarify the long-term cancer risk. Methods: This register-based nationwide emulated trial includes all Danes initiating treatment with GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i) 2007-2019, propensity score matched 1:1 on baseline characteristics and followed 10 years. The primary outcome was risk differences for cancer, estimated for long-term sustained use of GLP-1RA vs DPP-4i using g-computation accounting for time-varying patient characteristics. Secondary outcomes included "death without prior cancer" and the composite outcome "death or cancer". Analyses included sex stratified estimates and Cox hazard ratios (HR). Findings: After 195,702 person-years 4758 developed cancer. Among sustained users of GLP-1RA, 4·1 (95% CI 0·4-7·2) more patients developed cancer per 100, compared to 100 DPP-4i patients 10-years post-initiation (HR: 1·35 95% CI 1·05-1·73 6-10 years post-initiation). The excess cancer risk was 6·6 (95% CI 1·8-10·7) per 100 women and 2·2 (95% CI -2·2 to 6·2) per 100 men. Fewer patients "died without prior cancer" in users of GLP-1RA (per 100 users: -4·9 95% CI -7·6 to -2·4). There was no difference in risk of "death or cancer" per 100 users: -1·15 (95% CI -4·9 to 2·5). Interpretation: Long-term sustained users of GLP-1RA had a small increased risk of cancer; potentially explained by a survival benefit. Residual confounding by body mass index cannot be ruled out. Funding: The Scientific Committee of the Danish Cancer Society (R354-A20492-23-S3 to LSM).
Gamborg et al. (Sat,) studied this question.